Treatment of methotrexate-refractory primary central nervous system lymphoma (PCNSL) at Memorial Sloan Kettering Cancer Center

Click to increase image sizeClick to decrease image size

Acknowledgments

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by SC and LM; statistical analysis was performed by AR. The first draft of the manuscript was prepared by SC and LM, and all authors edited previous versions of the manuscript. All authors read and approved the final manuscript.

Disclosure statement

The views expressed in this article are our own and not an official position of our institution. CG: ROCHE, BTG, ONO, Curis – consulting. LM, SC, and AR do not have any conflicts of interest to disclose.

Additional information

Funding

This research was funded in part through the NIH/NCI Cancer Center Support Grant [P30 CA008748].